Lamivudine/Maraviroc/Zidovudine

拉米夫定/马拉韦罗/齐多夫定

Report date: 2022/12/07 17:06:45

Base Information

Drug NameLamivudine/Maraviroc/Zidovudine
Drug Alias NameLamivudine/zidovudine/maravirocMaraviroc/lamivudine/zidovudineMaraviroc/zidovudine/lamivudineZidovudine/lamivudine/maravirocZidovudine/maraviroc/lamivudine +[6] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionHuman immunodeficiency virus type 1 reverse transcriptase inhibitorsReverse transcriptase inhibitorsC-C chemokine receptor type 5 antagonists
TargetsHuman immunodeficiency virus type 1 reverse transcriptaseC-C chemokine receptor type 5Reverse transcriptase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes LamivudineMaravirocZidovudine
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGlaxosmithkline Plc
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A